Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Can Osteoarthritis Be Reversed?

Elizabeth Hofheinz, MPH, MEd  |  Issue: November 2017  |  November 6, 2017

Jamie Dananberg, MD, is chief medical officer at Unity Biotechnology. He states, “Unity Biotechnology became interested in senescent cells nearly six years ago when one of our co-founders did some work in this area. When we were looking to further our work on senescent cells and arthritis, we reached out to Dr. Elisseeff.

“We knew it was critical to examine the biology underlying OA,” states Dr. Dananberg. “This condition is recognized as inflammatory, but no one understands exactly why inflammation is involved. We found that in the culture system from the human knee cartilage if you eliminate senescent cells then the remaining chondroyctes can produce type II collagen and aggrecan (the ingredients of cartilage). In an environment where you have the interplay of roughly 100 inflammatory molecules, if you remove just one or two it will have little impact. A better idea is to eliminate the actual senescent cells so you get rid of the underlying cause of OA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“In the Nature study published in early 2016, a culmination of our prior work, it was interesting to see that one of the significant phenotypes we identified was musculoskeletal.3 The animals involved actually had greater muscle mass, tensile strength and an absence of OA. The Nature Medicine work picked up from that and extended it to better understand OA.”

Throw Out the Dogma

“Thus far, we have only been able to offer patients symptom relief with medications, such as steroids and non-steroidal anti-inflammatory drugs. Something that has really struck us is that there is a lot of acquiescence in terms of standard of care. We are taught that bones are supposed to ache and creak—and that OA is just a part of getting old. Maybe it does not have to be like that … maybe it’s time to toss out the dogma. Our goal is to be working in the clinic with humans next year. The potential that we can intervene in the OA process is exceptional.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Elizabeth Hofheinz, MPH, MEd, is a freelance medical editor and writer based in the Greater New Orleans area.

References

  1. Osteoarthritis. Centers for Disease Control and Prevention. 2017 Sep 9 (reviewed).
  2. Jeon OH, Kim C, Laberge RM, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017 Jun;23(6):775–781.
  3. Baker, DJ, Childs BG, Durik M, et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016 Feb 11;530(7589):184–189.

Note: The study was conducted by scientists at UNITY Biotechnology, Johns Hopkins University, Buck Institute for Aging Research, Lawrence Berkeley National Laboratory, Mayo Clinic College of Medicine, Ulsan National Institute of Science and Technology, and the European Research Institute for the Biology of Aging.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch Rheum Tagged with:agingcartilage repaircellsdrugmiceOAOsteoarthritispreventResearchRheumatic DiseasesenescentstudytherapyTreatmentUBX0101

Related Articles

    Basics of Biologic Joint Reconstruction

    April 6, 2012

    For young patients especially, this can delay knee replacement and provide better outcomes.

    New Therapeutics for Osteoarthritis May Be in Sight

    April 1, 2015

    Overview of OA pathogenesis, recent discoveries suggest new treatment strategies are possible

    Post-Traumatic Osteoarthritis: Managing OA That Develops After Joint Injuries & Reconstructive Surgery

    November 28, 2018

    CHICAGO—Joint trauma is one of many potential drivers of osteoarthritis disease activity and structural progression. In Post-Traumatic OA: Pathogenesis, Clinical Evolution and Management, a session at the 2018 ACR/ARHP Annual Meeting, experts discussed the effects of sports and other injuries on even young patients’ joints. Post-traumatic osteoarthritis (OA) may account for 12% of hip, knee…

    Emerging Treatments for OA: New Therapies Target Joint Pain, Not Just Structural Damage

    November 28, 2018

    CHICAGO—Are effective treatments for osteoarthritis (OA) on the horizon? In Emerging Treatments for Osteoarthritis at the 2018 ACR/ARHP Annual Meeting, experts discussed potential therapies to address OA structural progression, pain and inflammation. With an aging population and rising obesity rates, “we can expect the prevalence of osteoarthritis will only increase,” said Anne-Marie Malfait, MD, PhD,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences